PFE (Pfizer) How high will it go? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go?

PFE 25.19

+0.6%

Dec 19 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JEB who wrote (6594)	1/1/1999 11:05:00 AM
From: BigKNY3	Read Replies (1) of 9523

Monsanto - FDA -2: Celebrex Not Considered New Drug Class By Otesa Middleton 12/31/98 Dow Jones News Service WASHINGTON (Dow Jones)--Monsanto Co.'s (MTC) Celebrex won approval from the U.S. Food and Drug Administration Thursday, making it the first Cox-2 inhibitor cleared by the agency. The FDA approved the drug for rheumatoid arthritis and osteoarthritis. The drug works by inhibiting the enzyme cyclooxygenase-2, called Cox-2, which causes inflammation. The agency's release said Celebrex is a member of the NSAID, or non-steroidal anti-inflammatory drug class, which includes ibuprofen, aspirin and other popular pain killers. One of the most common side effects of NSAIDs is gastrointestinal ulcers, which are believed to be caused because other NSAIDs block both Cox-1 and Cox-2. Cox-1 is thought to protect the stomach lining. "It is therefore hoped that Celebrex will have safety advantages compared to other NSAID products," the FDA's release said. When Monsanto applied for Celebrex's approval, the company asked the drug be considered the first in a new class of drugs that only work to inhibit Cox-2. A federal panel had advised the agency that the drug should still be considered an NSAID

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next